Interrupting and Resuming GLP-1 Therapy for Weight Loss May Reduce Drug

Interrupting and Resuming GLP-1 Therapy for Weight Loss May Reduce Drug

In recent years, GLP-1 receptor agonists such as semaglutide (marketed under brand names like Ozempic and Wegovy) have revolutionized the pharmacological landscape for weight management. These drugs, originally developed for type 2 diabetes, have gained significant popularity for their potent weight-loss effects. However, new preclinical research from the Perelman School of Medicine at the University […]

Inconsistent use of GLP-1s may make the drug less effective

Inconsistent use of some GLP-1 weight-loss medications, like Ozempic and Wegovy, may significantly lessen their effectiveness, according to a preclinical study from researchers at the Perelman School of Medicine at the University of Pennsylvania. The study showed that each time overweight mice stopped and restarted GLP-1s, they dropped less and less weight compared their original weight-loss. “The effectiveness of these medications may depend he…